Edity Therapeutics

📍 Rehovot, Israel🗓 Founded 2020👥 21 employees💰 Last funded Oct 2022
Edity is developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Our technology allows for precise modulation of intracellular pathways of disease using a range of proteins including gene editors, immune sensors, enzymes and intrabodies.
4
Total investors
4
Early stage
0
Mid stage
0
Late stage
2020
Founded
Investor geography3 countries
United States
2
Israel
1
Germany
1
Investor activity2020–2022 · investors recorded per year
2020220222
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Edity Therapeutics?
Edity Therapeutics has 4 investors on record on gritt.io, including 4 early-stage backers.
When did Edity Therapeutics last raise funding?
The most recent investment in Edity Therapeutics recorded on gritt.io was in October 2022.
When was Edity Therapeutics founded?
Edity Therapeutics was founded in 2020.
What industry is Edity Therapeutics in?
Edity Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Edity Therapeutics based?
Edity Therapeutics is headquartered in Rehovot, Israel.